HCC Immunotherapy

We collected additional tumor tissues from the initial resection of two early-stage HCC patients for Stereo-seq. These patients were later put on immunotherapy with atezolizumab + bevacizumab after the recurrence and exhibited a clinical response (M311) or resistance (M316) to the combination therapy.

我们为开展Stereo-seq测序，从两名早期肝细胞癌（Hepatocellular carcinoma, HCC）患者的初次手术切除标本中采集了额外的肿瘤组织。上述两名患者在肿瘤复发后，接受了阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）的免疫治疗，并分别对该联合疗法表现出临床应答（M311）与治疗耐药（M316）。

搜集汇总

背景与挑战

背景概述

该数据集收集了两名早期肝细胞癌（HCC）患者的肿瘤组织样本，使用Stereo-seq技术进行测序分析，旨在研究免疫治疗（atezolizumab + bevacizumab联合疗法）的响应机制。数据集包含两个文件，分别对应临床响应（M311）和耐药（M316）的样本，适用于肿瘤免疫学和癌症治疗研究。